{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:14:36Z","timestamp":1790435676908,"version":"4.1.0"},"reference-count":153,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T00:00:00Z","timestamp":1608681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>In the last few years, monoclonal antibodies (mAbs) such as elotuzumab and daratutumab have brought the treatment of multiple myeloma (MM) into the new era of immunotherapy. More recently, chimeric antigen receptor (CAR) modified T cell, a novel cellular immunotherapy, has been developed for treatment of relapsed\/refractory (RR) MM, and early phase clinical trials have shown promising efficacy of CAR T cell therapy. Many patients with end stage RRMM regard CAR T cell therapy as their \u201clast chance\u201d and a \u201chope of cure\u201d. However, severe adverse events (AEs) and even toxic death related to CAR T cell therapy have been observed. The management of AEs related to CAR T cell therapy represents a new challenge, as the pathophysiology is not fully understood and there is still no well-established standard of management. With regard to CAR T cell associated toxicities in MM, in this review, we will provide an overview of experience from clinical trials, pathophysiology, and management strategies.<\/jats:p>","DOI":"10.3389\/fimmu.2020.620312","type":"journal-article","created":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T09:09:56Z","timestamp":1608714596000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":45,"title":["Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies"],"prefix":"10.3389","volume":"11","author":[{"given":"Xiang","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Rasche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Martin","family":"Kort\u00fcm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Danhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hudecek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,12,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.7861\/clinmedicine.19-1-58","article-title":"Haematology: multiple myeloma","volume":"19","author":"Firth","year":"2019","journal-title":"Clin Med (Lond)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am J Hematol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ctrv.2018.09.001","article-title":"Drug resistance in multiple myeloma","volume":"70","author":"Robak","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: A unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19113613","article-title":"Immunotherapy: A Novel Era of Promising Treatments for Multiple Myeloma","volume":"19","author":"Castella","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.5001\/omj.2013.02","article-title":"Multiple myeloma: an update","volume":"28","author":"Al-Farsi","year":"2013","journal-title":"Oman Med J"},{"key":"B8","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.clml.2020.03.017","article-title":"Clinical Updates Regarding Multiple Myeloma From the 2019 American Society of Hematology Annual Meeting","volume":"20","author":"Terpos","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9072166","article-title":"Bispecific Antibodies: A New Era of Treatment for Multiple Myelomsa","volume":"9","author":"Zhou","year":"2020","journal-title":"J Clin Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0930-x","article-title":"Development of CAR-T cell therapies for multiple myeloma","volume":"34","author":"Gagelmann","year":"2020","journal-title":"Leukemia"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-113220","article-title":"Low Dose of Human scFv-Derived BCMA-Targeted CAR-T Cells Achieved Fast Response and High Complete Remission in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"132","author":"Jiang","year":"2018","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.034","article-title":"Clinical Responses and Pharmacokinetics of fully human BCMA Targeting CAR T Cell Therapy in Relapsed\/Refractory Multiple Myeloma","volume":"19","author":"Li","year":"2019","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-117729","article-title":"Fully Human Bcma Targeted Chimeric Antigen Receptor T Cells Administered in a Defined Composition Demonstrate Potency at Low Doses in Advanced Stage High Risk Multiple Myeloma","volume":"132","author":"Green","year":"2018","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12943-019-1092-1","article-title":"Recent updates on CAR T clinical trials for multiple myeloma","volume":"18","author":"Lin","year":"2019","journal-title":"Mol Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2018.03.002","article-title":"CARs and other T cell therapies for MM: The clinical experience","volume":"31","author":"Danhof","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000667","article-title":"Clinical data, limitations and perspectives on chimeric antigen receptor T-cell therapy in multiple myeloma","volume":"32","author":"Beauvais","year":"2020","journal-title":"Curr Opin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01243","article-title":"CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions","volume":"10","author":"Rodriguez-Lobato","year":"2020","journal-title":"Front Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2414","article-title":"Advances in CAR T Therapy for Hematologic Malignancies","volume":"40","author":"Freyer","year":"2020","journal-title":"Pharmacotherapy"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta \/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat Biotechnol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01985","article-title":"Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes","volume":"11","author":"Schultz","year":"2020","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3324\/haematol.2019.229781","article-title":"Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)","volume":"105","author":"Yakoub-Agha","year":"2020","journal-title":"Haematologica"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050732","article-title":"Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells","volume":"202","author":"Gattinoni","year":"2005","journal-title":"J Exp Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-621474","article-title":"Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs","volume":"125","author":"Ninomiya","year":"2015","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-03-900928","article-title":"CAR-T efficacy: is conditioning the key","volume":"133","author":"Neelapu","year":"2019","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1097\/HS9.0000000000000186","article-title":"CAR T Cell Toxicity: Current Management and Future Directions","volume":"3","author":"Yanez","year":"2019","journal-title":"Hemasphere"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1716266115","article-title":"Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity","volume":"115","author":"Davenport","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061283","article-title":"Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells","volume":"20","author":"Benmebarek","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/10.11.1693","article-title":"The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily","volume":"10","author":"Madry","year":"1998","journal-title":"Int Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1205868","article-title":"Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays","volume":"21","author":"De Vos","year":"2002","journal-title":"Oncogene"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-1984","article-title":"BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone","volume":"103","author":"Moreaux","year":"2004","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2043","article-title":"Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival","volume":"103","author":"Novak","year":"2004","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24954","article-title":"Efficacy of VDT PACE-like regimens in treatment of relapsed\/refractory multiple myeloma","volume":"93","author":"Lakshman","year":"2018","journal-title":"Am J Hematol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2023-2","article-title":"The lymphoma-like polychemotherapy regimen \u201cDexa-BEAM\u201d in advanced and extramedullary multiple myeloma","volume":"93","author":"Rasche","year":"2014","journal-title":"Ann Hematol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12041035","article-title":"Carfilzomib Based Treatment Strategies in the Management of Relapsed\/Refractory Multiple Myeloma with Extramedullary Disease","volume":"12","author":"Zhou","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1819745116","article-title":"Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma","volume":"116","author":"Xu","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"key":"B42","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26792","article-title":"Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma","volume":"10","author":"Sun","year":"2019","journal-title":"Oncotarget"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504542","article-title":"Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma","volume":"373","author":"Garfall","year":"2015","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.205","article-title":"T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells","volume":"26","author":"Mihara","year":"2012","journal-title":"Leukemia"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1172\/JCI86000","article-title":"Clinical responses with T lymphocytes targeting malignancy-associated kappa light chains","volume":"126","author":"Ramos","year":"2016","journal-title":"J Clin Invest"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-778423","article-title":"SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7(+) normal lymphocytes","volume":"130","author":"Gogishvili","year":"2017","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.03.016","article-title":"Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector","volume":"26","author":"Smith","year":"2018","journal-title":"Mol Ther"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-117974","article-title":"Phase I-IIa Clinical Trial to Assess Safety and Efficacy of MLM-CAR44.1, a CD44v6 Directed CAR-T in Relapsed\/Refractory Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)","volume":"132","author":"Carrabba","year":"2018","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0307","article-title":"Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML\/MDS and Multiple Myeloma","volume":"7","author":"Baumeister","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-130340","article-title":"A Bispecific CAR-T Cell Therapy Targeting Bcma and CD38 for Relapsed\/Refractory Multiple Myeloma: Updated Results from a Phase 1 Dose-Climbing Trial","volume":"134","author":"Li","year":"2019","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1038\/s41467-020-16160-5","article-title":"Systematically optimized BCMA\/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma","volume":"11","author":"Zah","year":"2020","journal-title":"Nat Commun"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126689","article-title":"Phase 1 First-in-Human Study of AUTO2, the First Chimeric Antigen Receptor (CAR) T Cell Targeting APRIL for Patients with Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"134","author":"Popat","year":"2019","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-131056","article-title":"A Bcma and CD19 Bispecific CAR-T for Relapsed and Refractory Multiple Myeloma","volume":"134","author":"Zhang","year":"2019","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-113548","article-title":"JCARH125, Anti-BCMA CAR T-cell Therapy for Relapsed\/Refractory Multiple Myeloma: Initial Proof of Concept Results from a Phase 1\/2 Multicenter Study (EVOLVE)","volume":"132","author":"Mailankody","year":"2018","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8504","article-title":"Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed\/refractory multiple myeloma (RRMM): update of the phase 1\/2 EVOLVE study (NCT03430011)","volume":"38","author":"Mailankody","year":"2020","journal-title":"J Clin Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-119717","article-title":"Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed\/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial","volume":"132","author":"Mailankody","year":"2018","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129562","article-title":"Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed\/Refractory (r\/r) Multiple Myeloma (MM) (PRIME)","volume":"134","author":"Costello","year":"2019","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126660","article-title":"Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy","volume":"134","author":"Berdeja","year":"2019","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8505","article-title":"Update of CARTITUDE-1: A phase Ib\/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed\/refractory multiple myeloma","volume":"38","author":"Berdeja","year":"2020","journal-title":"J Clin Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8503","article-title":"Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results","volume":"38","author":"Munshi","year":"2020","journal-title":"J Clin Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.2535","article-title":"The phase I clinical study of CART targeting BCMA with humanized alpaca-derived single-domain antibody as antigen recognition domain","volume":"37","author":"Han","year":"2019","journal-title":"J Clin Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127608","article-title":"Efficacy and Safety of CAR-T Therapy with Safety Switch Targeting Bcma for Patients with Relapsed\/Refractory Multiple Myeloma in a Phase 1 Clinical Study","volume":"134","author":"Fu","year":"2019","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126104","article-title":"Phase 1 Trial of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells in Relapsed\/Refractory Multiple Myeloma","volume":"134","author":"Jie","year":"2019","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jocit.2014.11.001","article-title":"CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma","volume":"2","author":"Guo","year":"2016","journal-title":"J Cell Immunother"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.120505","article-title":"Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma","volume":"3","author":"Garfall","year":"2018","journal-title":"JCI Insight"},{"key":"B68","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1182\/blood-2019-129740","article-title":"Sequential CD19- and Bcma-Specific Chimeric Antigen Receptor T Cell Treatment for RRMM: Report from a Single Center Study","volume":"134","author":"Yan","year":"2019","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-131546","article-title":"Combined Infusion of Anti-CD19 and Anti-Bcma CART Cells after Early or Later Transplantation in the Front Line Was Superior to Salvage Therapy for High Risk MM","volume":"134","author":"Shi","year":"2019","journal-title":"Blood"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial","volume":"6","author":"Yan","year":"2019","journal-title":"Lancet Haematol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002509","article-title":"Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B75","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"key":"B78","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/nri2448","article-title":"Exploring the full spectrum of macrophage activation","volume":"8","author":"Mosser","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40164-020-00171-5","article-title":"Macrophage, the potential key mediator in CAR-T related CRS","volume":"9","author":"Hao","year":"2020","journal-title":"Exp Hematol Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2005.06.090","article-title":"Catecholamines mediate stress-induced increases in peripheral and central inflammatory cytokines","volume":"135","author":"Johnson","year":"2005","journal-title":"Neuroscience"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/nature06185","article-title":"Phagocyte-derived catecholamines enhance acute inflammatory injury","volume":"449","author":"Flierl","year":"2007","journal-title":"Nature"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3321","article-title":"Transcription factor Nr4a1 couples sympathetic and inflammatory cues in CNS-recruited macrophages to limit neuroinflammation","volume":"16","author":"Shaked","year":"2015","journal-title":"Nat Immunol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0602-5","article-title":"Insight into mechanisms associated with cytokine release syndrome and neurotoxicity after CD19 CAR-T cell immunotherapy","volume":"54","author":"Chou","year":"2019","journal-title":"Bone Marrow Transpl"},{"key":"B85","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_238691","article-title":"The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden","volume":"39","author":"Santomasso","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000746","article-title":"How I treat adverse effects of CAR-T cell therapy","volume":"4","author":"Yanez","year":"2020","journal-title":"ESMO Open"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14403","article-title":"Chimeric antigen receptor T-cell therapy toxicities","author":"Greenbaum","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01973","article-title":"Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies","volume":"11","author":"Siegler","year":"2020","journal-title":"Front Immunol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"B91","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-018-0571-y","article-title":"Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel","volume":"11","author":"Porter","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"B93","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000952","article-title":"Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management","volume":"4","author":"Pennisi","year":"2020","journal-title":"Blood Adv"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz053","article-title":"Neurological toxicities associated with chimeric antigen receptor T-cell therapy","volume":"142","author":"Rubin","year":"2019","journal-title":"Brain"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J Clin Oncol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J Clin Oncol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2020-002550","article-title":"Neurotoxicity-CAR T-cell therapy: what the neurologist needs to know","volume":"20","author":"Neill","year":"2020","journal-title":"Pract Neurol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.2703","article-title":"Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy","author":"Rubin","year":"2020","journal-title":"JAMA Neurol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00885","article-title":"Recognizing and Grading CAR T-Cell Toxicities: An Advanced Practitioner Perspective","volume":"10","author":"Sievers","year":"2020","journal-title":"Front Oncol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25359","article-title":"Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma","volume":"9","author":"Bu","year":"2018","journal-title":"Oncotarget"},{"key":"B110","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"key":"B111","doi-asserted-by":"publisher","first-page":"e0126007","DOI":"10.1371\/journal.pone.0126007","article-title":"CD38 is expressed on inflammatory cells of the intestine and promotes intestinal inflammation","volume":"10","author":"Schneider","year":"2015","journal-title":"PLoS One"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(95)00885-T","article-title":"Neuronal localization of CD38 antigen in the human brain","volume":"697","author":"Mizuguchi","year":"1995","journal-title":"Brain Res"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M308034200","article-title":"CD38 signaling in T cells is initiated within a subset of membrane rafts containing Lck and the CD3-zeta subunit of the T cell antigen receptor","volume":"278","author":"Munoz","year":"2003","journal-title":"J Biol Chem"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01613","article-title":"Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen","volume":"10","author":"Timmers","year":"2019","journal-title":"Front Immunol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40364-018-0116-0","article-title":"Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy","volume":"6","author":"Wang","year":"2018","journal-title":"Biomark Res"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.08.015","article-title":"Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed\/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy","volume":"25","author":"Jain","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13300","article-title":"Role of virological serum markers in patients with both hepatitis B virus infection and diffuse large B-cell lymphoma","volume":"103","author":"Zhou","year":"2019","journal-title":"Eur J Haematol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13388","article-title":"Serological hepatitis B virus (HBV) activity in patients with HBV infection and B-cell non-Hodgkin\u2019s lymphoma","volume":"104","author":"Zhou","year":"2020","journal-title":"Eur J Haematol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3058-y","article-title":"The influence of rituximab-containing chemotherapy on HCV load in patients with HCV-associated non-Hodgkin\u2019s lymphomas","volume":"96","author":"Zhou","year":"2017","journal-title":"Ann Hematol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.0287","article-title":"The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.10.038","article-title":"Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)","volume":"74","author":"Alvi","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006216","article-title":"Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19","volume":"136","author":"Frigault","year":"2020","journal-title":"Blood"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.2296.2296","article-title":"Refractory Cytokine Release Syndrome in Recipients of Chimeric Antigen Receptor (CAR) T Cells","volume":"124","author":"Frey","year":"2014","journal-title":"Blood"},{"key":"B126","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1046\/j.1365-2036.1996.22164025.x","article-title":"Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies","author":"Brattsand","year":"1996","journal-title":"Aliment Pharmacol Ther"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126081","article-title":"Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed\/Refractory Large B Cell Lymphoma","volume":"134","author":"Topp","year":"2019","journal-title":"Blood"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123051","article-title":"Corticosteroids Do Not Influence the Efficacy and Kinetics of CAR-T Cells for B-Cell Acute Lymphoblastic Leukemia","volume":"134","author":"Liu","year":"2019","journal-title":"Blood"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.652.652","article-title":"Ruxolitinib Prevents Cytokine Release Syndrome after CART Cell Therapy without Impairing the Anti-Tumor Effect in a Xenograft Model","volume":"128","author":"Kenderian","year":"2016","journal-title":"Blood"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.262","article-title":"Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms","volume":"31","author":"Ruella","year":"2017","journal-title":"Leukemia"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-020-02840-x","article-title":"Progressive multifocal leukoencephalopathy after CAR T therapy","volume":"112","author":"Sdrimas","year":"2020","journal-title":"Int J Hematol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A6184","article-title":"Chimeric Antigen Receptor T-Cell Neurotoxicity Neuroimaging: More Than Meets the Eye","volume":"40","author":"Gust","year":"2019","journal-title":"AJNR Am J Neuroradiol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A6042","article-title":"Chimeric Antigen Receptor T-Cell Therapy: What the Neuroradiologist Needs to Know","volume":"40","author":"Valand","year":"2019","journal-title":"AJNR Am J Neuroradiol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-12-893396","article-title":"Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells","volume":"133","author":"Karschnia","year":"2019","journal-title":"Blood"},{"key":"B135","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2147\/EB.S69174","article-title":"Papilledema: epidemiology, etiology, and clinical management","volume":"7","author":"Rigi","year":"2015","journal-title":"Eye Brain"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002228","article-title":"Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Strati","year":"2020","journal-title":"Blood Adv"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-05-846428","article-title":"Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques","volume":"132","author":"Nellan","year":"2018","journal-title":"Blood"},{"key":"B138","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1080\/17474086.2019.1585238","article-title":"Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy","volume":"12","author":"Acharya","year":"2019","journal-title":"Expert Rev Hematol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15644","article-title":"Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy","volume":"183","author":"Hay","year":"2018","journal-title":"Br J Haematol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018020198","article-title":"No free rides: management of toxicities of novel immunotherapies in ALL, including financial","volume":"2","author":"Jain","year":"2018","journal-title":"Blood Adv"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2010.03.022","article-title":"The serum and cerebrospinal fluid pharmacokinetics of anakinra after intravenous administration to non-human primates","volume":"223","author":"Fox","year":"2010","journal-title":"J Neuroimmunol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001626","article-title":"Intrathecal chemotherapy for management of steroid-refractory CAR T-cell-associated neurotoxicity syndrome","volume":"4","author":"Shah","year":"2020","journal-title":"Blood Adv"},{"key":"B144","doi-asserted-by":"publisher","first-page":"e202072","DOI":"10.1001\/jamanetworkopen.2020.2072","article-title":"Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma","volume":"3","author":"Lyman","year":"2020","journal-title":"JAMA Netw Open"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2008.001677","article-title":"Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy","volume":"94","author":"Griffioen","year":"2009","journal-title":"Haematologica"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1172\/JCI84813","article-title":"Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia","volume":"126","author":"Paszkiewicz","year":"2016","journal-title":"J Clin Invest"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1089\/hgtb.2012.050","article-title":"Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells","volume":"23","author":"Marin","year":"2012","journal-title":"Hum Gene Ther Methods"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1449","article-title":"Redirecting gene-modified T cells toward various cancer types using tagged antibodies","volume":"18","author":"Tamada","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B149","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1038\/s41467-019-10565-7","article-title":"Regulation of CAR T cell-mediated cytokine release syndrome-like toxicity using low molecular weight adapters","volume":"10","author":"Lee","year":"2019","journal-title":"Nat Commun"},{"key":"B150","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","article-title":"GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts","volume":"133","author":"Sterner","year":"2019","journal-title":"Blood"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-676924","article-title":"Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure","volume":"127","author":"Richardson","year":"2016","journal-title":"Blood"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2016.09.014","article-title":"Defibrotide for the management of sinusoidal obstruction syndrome in patients who undergo haemopoietic stem cell transplantation","volume":"50","author":"Coutsouvelis","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"B153","doi-asserted-by":"publisher","first-page":"eaau5907","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci Transl Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.620312\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T09:09:59Z","timestamp":1608714599000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.620312\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,23]]},"references-count":153,"alternative-id":["10.3389\/fimmu.2020.620312"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.620312","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,23]]},"article-number":"620312"}}